HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH TRANSFUSION BURDEN IN OLDER US PATIENTS WITH RELAPSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA WHO WERE PRESCRIBED GILTERITINIB: A MEDICARE CLAIMS-BASED COHORT STUDY
Author(s)
Priti Pednekar, PhD1, Alana Block, PharmD, BCOP1, Christopher Young, PhD1, Giridharan Gurumoorthy, MSc1, Peter Kardel, MA2, Thomas W. LeBlanc, MD, MA3;
1Astellas Pharma Global Development Inc., Northbrook, IL, USA, 2ADVI Health LLC, Washington, DC, USA, 3Duke University Medical Center, Durham, NC, USA
1Astellas Pharma Global Development Inc., Northbrook, IL, USA, 2ADVI Health LLC, Washington, DC, USA, 3Duke University Medical Center, Durham, NC, USA
OBJECTIVES: Older patients with relapsed acute myeloid leukemia (AML) often require transfusion support due to persistent cytopenias from disease progression and targeted therapy. This study describes healthcare resource utilization (HRU) and costs associated with transfusion burden among Medicare beneficiaries with relapsed FLT3-mutated AML who were prescribed gilteritinib.
METHODS: This observational retrospective cohort study utilized Medicare Parts A-D claims and enrollment data from July 2016-December 2024. Patients diagnosed with relapsed FLT3-mutated AML who were prescribed gilteritinib, were aged ≥65 years at the index date, and had ≥180 days continuous enrollment before diagnosis were included. The index date was the first prescription fill date for gilteritinib. Transfusion independence (TI) was defined as a continuous 56-day period without any red blood cell (RBC) or platelet (PLT) transfusions, assessed on a rolling basis. HRU and costs were evaluated for TI and transfusion dependence (TD) periods.
RESULTS: Of 799 eligible patients (mean age: 74.6 years), 55.6% and 64.3% had ≥1 period of RBC TI and PLT TI, respectively. Most were male (52.9%) and White (84.7%). Mean Charlson Comorbidity Index was 2.9; median follow-up was 136 days; mean treatment duration was 21.1 weeks. Median inpatient stay was significantly shorter during TI than TD for both RBC (7 vs 27 days, p<0.0001) and PLT (7 vs 24 days, p<0.0001). Mean PPPM visits were significantly lower during TI than TD periods for inpatient hospitalizations with prior emergency department visit (RBC: 0.2 vs 0.3, p=0.0013; PLT: 0.2 vs 0.3, p<0.0001), outpatient visits (RBC: 1.8 vs 3.3, p<0.0001; PLT: 1.7 vs 3.2, p<0.0001), and outpatient physician visits (RBC: 6.7 vs 15.8, p<0.0001; PLT: 7.2 vs 15.8, p<0.0001). Costs were significantly lower for TI versus TD in these HRU categories.
CONCLUSIONS: TI was associated with lower HRU and costs versus TD among Medicare beneficiaries with relapsed FLT3-mutated AML who were prescribed gilteritinib.
METHODS: This observational retrospective cohort study utilized Medicare Parts A-D claims and enrollment data from July 2016-December 2024. Patients diagnosed with relapsed FLT3-mutated AML who were prescribed gilteritinib, were aged ≥65 years at the index date, and had ≥180 days continuous enrollment before diagnosis were included. The index date was the first prescription fill date for gilteritinib. Transfusion independence (TI) was defined as a continuous 56-day period without any red blood cell (RBC) or platelet (PLT) transfusions, assessed on a rolling basis. HRU and costs were evaluated for TI and transfusion dependence (TD) periods.
RESULTS: Of 799 eligible patients (mean age: 74.6 years), 55.6% and 64.3% had ≥1 period of RBC TI and PLT TI, respectively. Most were male (52.9%) and White (84.7%). Mean Charlson Comorbidity Index was 2.9; median follow-up was 136 days; mean treatment duration was 21.1 weeks. Median inpatient stay was significantly shorter during TI than TD for both RBC (7 vs 27 days, p<0.0001) and PLT (7 vs 24 days, p<0.0001). Mean PPPM visits were significantly lower during TI than TD periods for inpatient hospitalizations with prior emergency department visit (RBC: 0.2 vs 0.3, p=0.0013; PLT: 0.2 vs 0.3, p<0.0001), outpatient visits (RBC: 1.8 vs 3.3, p<0.0001; PLT: 1.7 vs 3.2, p<0.0001), and outpatient physician visits (RBC: 6.7 vs 15.8, p<0.0001; PLT: 7.2 vs 15.8, p<0.0001). Costs were significantly lower for TI versus TD in these HRU categories.
CONCLUSIONS: TI was associated with lower HRU and costs versus TD among Medicare beneficiaries with relapsed FLT3-mutated AML who were prescribed gilteritinib.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE161
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology